Key result
Rosuvastatin-loaded hydrogel improves stem cell therapy for cardiac repair by mitigating local immune responses.
Why the study?
Stem cell therapy for cardiac repair needs improved clinical effectiveness by modulating the local immune response in the infarcted heart against transplanted stem cells.
Does an immunomodulatory chitosan-rosuvastatin hydrogel loaded with MSCs improve stem cell retention and cardiac function in a rat model of myocardial infarction?
Does an immunomodulatory chitosan-rosuvastatin hydrogel loaded with MSCs improve stem cell retention and cardiac function in a rat model of myocardial infarction?
A novel rosuvastatin-loaded hydrogel improves the survival and efficacy of transplanted mesenchymal stem cells for cardiac repair in a rat model of myocardial infarction by modulating the local immune response.
Hypothesis-generating for statin-loaded hydrogels in stem cell cardiac repair; leaves open translation to human MI therapy.
In clinical trials allogeneic mesenchymal stem cells (MSCs) from young and healthy donors have shown promise to repair the heart following a heart attack. However, immune rejection of transplanted MSCs has prevented the clinical translation of stem cells-based therapies for cardiac patients. Therefore, strategies to improve survival of implanted stem cells in the heart would be of immense therapeutic value. This study presents the development of a novel immunomodulatory chitosan-rosuvastatin (CR) hydrogel loaded with MSCs for cardiac repair. The hydrogel showed excellent 3 dimensional (3D) structure and porosity, and was found to support the growth of MSCs. In an in vivo rat model of myocardial infarction (MI), the immunomodulatory CR hydrogel provided physical bulk, improved the retention of MSCs and cardiac function at 4 weeks after MI. The RNA sequencing data demonstrate that rosuvastatin improved the “stemness” of MSCs and reduced the activation of T-cells, downregulated T H1 polarization in response to inflammatory stress in the infarcted heart. Therefore, the current study presents a new paradigm in improving clinical effectiveness of stem cell therapy for cardiac repair by modulating local immune response in the heart against transplanted stem cells using a novel immunomodulatory CR hydrogel.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied Myocardial infarction. Chitosan-rosuvastatin (CR) hydrogel loaded with MSCs was evaluated on Retention of MSCs and cardiac function. In a rat model of myocardial infarction, an immunomodulatory chitosan-rosuvastatin hydrogel improved the retention of mesenchymal stem cells and cardiac function at 4 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: